Goldman Sachs Group Inc Vigil Neuroscience, Inc. Transaction History

Goldman Sachs Group Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.51 - $4.66 $961,078 - $1.78 Million	382,900 Added 2099.35%	401,139 $1.6 Million
Q1 2024 May 15, 2024	SELL	$2.68 - $3.63 $179,187 - $242,705	-66,861 Reduced 78.57%	18,239 $62,000
Q4 2023 Feb 13, 2024	SELL	$2.97 - $8.6 $181,472 - $525,477	-61,102 Reduced 41.79%	85,100 $287,000
Q3 2023 May 14, 2024	BUY	$4.8 - $9.92 $293,289 - $606,131	61,102 Added 71.8%	146,202 $788,000
Q3 2023 Nov 14, 2023	BUY	$4.8 - $9.92 $639,331 - $1.32 Million	133,194 Added 1023.94%	146,202 $788,000
Q2 2023 May 14, 2024	SELL	$8.11 - $10.54 $95,843 - $124,561	-11,818 Reduced 47.6%	13,008 $122,000
Q2 2023 Aug 14, 2023	SELL	$8.11 - $10.54 $95,843 - $124,561	-11,818 Reduced 47.6%	13,008 $122,000
Q1 2023 May 14, 2024	SELL	$8.77 - $12.7 $422,582 - $611,949	-48,185 Reduced 66.0%	24,826 $243,000
Q1 2023 May 11, 2023	SELL	$8.77 - $12.7 $422,582 - $611,949	-48,185 Reduced 66.0%	24,826 $243,000
Q4 2022 May 14, 2024	SELL	$8.74 - $15.99 $113 - $207	-13 Reduced 0.02%	73,011 $912,000
Q4 2022 Feb 13, 2023	SELL	$8.74 - $15.99 $113 - $207	-13 Reduced 0.02%	73,011 $912,000
Q3 2022 May 14, 2024	SELL	$2.37 - $9.61 $125 - $509	-53 Reduced 0.07%	73,024 $665,000
Q3 2022 Nov 10, 2022	SELL	$2.37 - $9.61 $125 - $509	-53 Reduced 0.07%	73,024 $0
Q2 2022 May 14, 2024	SELL	$2.23 - $7.81 $26,811 - $93,899	-12,023 Reduced 14.13%	73,077 $189,000
Q2 2022 Aug 15, 2022	SELL	$2.23 - $7.81 $1,699 - $5,951	-762 Reduced 1.03%	73,077 $189,000
Q1 2022 May 16, 2022	BUY	$7.03 - $17.29 $519,088 - $1.28 Million	73,839 New	73,839 $519,000

27.9M

Ticker VIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,268,600
Market Cap $90.2M
Description
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.